So, I get that know one loans cash without some incentive, streeterville is either getting paid back with interest or shares. The share payback only works if streeterville feels the shares are worth something and will be worth more. The thing that concerns me about these deals is the same that issue we had with the Paulson raises. If the share price Is low, they get paid back with more shares. The problem is as soon as they get there shares they sell them to keep the share price low so the next payback is as many shares as possible. For the Paulson deals it was to get as many shares in each raise, and there was absolutely pressure that lowered the stock price as time went by. We now have way more volume so it may not be as noticeable, but it is odd how the stock price sits at $3. I how others here can educate me if I’m wrong.
I do think there is always a cost to keep things going for a pre revenue company, but it is strange that this deal was done if the revenue from the Phillipines was soon. The raise 2 weeks ago was clearly earmarked for inventory production, this raise was not really explained, so it is for operations. Nader in proactive repeated the 1.2 million vials as inventor, which is the same as it has been except I am assuming we now actually paid Samsung.
I do think there is always a cost to keep things going for a pre revenue company, but it is strange that this deal was done if the revenue from the Phillipines was soon. The raise 2 weeks ago was clearly earmarked for inventory production, this raise was not really explained, so it is for operations. Nader in proactive repeated the 1.2 million vials as inventor, which is the same as it has been except I am assuming we now actually paid Samsung.
